<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171313</url>
  </required_header>
  <id_info>
    <org_study_id>XP-C-069</org_study_id>
    <secondary_id>XenoPort</secondary_id>
    <nct_id>NCT01171313</nct_id>
  </id_info>
  <brief_title>A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects</brief_title>
  <official_title>A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XenoPort, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XenoPort, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of XP21279/Carbidopa in
      comparison to Sinemet as well as evaluate the pharmacokinetics (PK) of levodopa after
      administration of XP21279/Carbidopa and Sinemet and to explore exposure-response
      relationships in a subset of subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in mean daily &quot;off&quot; time at end of double-blind maintenance treatment periods.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders (&quot;much improved&quot; or &quot;very much improved&quot;) on Investigator-rated and patient-rated CGI-I at end of double-blind Maintenance Treatment periods</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP21279 and carbidopa (experimental)</intervention_name>
    <description>Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet (comparator)</intervention_name>
    <description>Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for XP21279 and carbidopa</intervention_name>
    <description>Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Sinemet</intervention_name>
    <description>Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have predictable motor fluctuations of the wearing off type, defined by
             meeting the following criteria based on the on/off diaries recorded over 3 days in the
             Screening Period:

               -  Wearing-off in at least half (50%) of inter-dose intervals between the first and
                  the last daily doses averaged over the 3 diary days, and

               -  An average daily &quot;off&quot; time of 2 hours after the first &quot;on&quot; of the day through
                  awake time up to midnight.

          2. Subjects must be on one of the following stable QID or 5 times daily regimens for at
             least 4 weeks prior to Screening: Sinemet® or carbidopa-levodopa, with a total daily
             dose ranging from 400 mg to 1000 mg of levodopa

        Exclusion Criteria:

          1. History, signs, or symptoms suggesting the diagnosis of secondary or atypical
             Parkinsonism.

          2. Subject has moderately or severely disabling dyskinesias for greater than 25% of the
             waking day

          3. Subjects who have significant neurological symptoms not accounted for by Parkinson's
             disease

          4. Subjects who are taking Sinemet® CR, Parcopa®, concomitant COMT inhibitors (i.e.,
             entacapone or tolcapone), Stalevo®, or benserazide containing levodopa preparations
             Madopar® or Prolopa®.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Chen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>XenoPort, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <disposition_first_submitted>January 31, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 4, 2013</disposition_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

